Original InvestigationRisk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study
Under a Creative Commons license
open access
Key Words
functional status
HeartMate II
quality of life
risk/benefit analysis
ROADMAP
Abbreviations and Acronyms
6MWD
6-min walk distance
DT
destination therapy
EPPY
events per patient-year
EQ-5D
EuroQol
HF
heart failure
HMII
HeartMate II
HRQoL
health related quality of life
INTERMACS
Interagency Registry for Mechanically Assisted Circulatory Support
LVAD
left ventricular assist device
NYHA
New York Heart Association
OMM
optimal medical management
PHQ-9
Patient Health Questionnaire–9
VAS
visual analog scale
Cited by (0)
The ROADMAP trial was sponsored and conducted by Thoratec Corporation. Drs. Estep, Starling, Horstmanshof, Shah, Loebe, Moazami, Long, Milano, Stehlik, Kasirajan, Haas, and Rogers have received grant/research support from Thoratec. Drs. Estep, Horstmanshof, and Boyle have served as consultants for Thoratec. Dr. Estep has served as a consultant for Maquet. Dr. Starling has served as a member of the steering committee for Thoratec. Dr. Haas served on the Thoratec speakers bureau. Dr. Kasirajan served as a consultant for Syncardia. Drs. O’Connell and Farrar are Thoratec employees. Dr. Farrar is a Thoratec stockholder. Dr. Selzman has reported that he has no relationships relevant to the contents of this paper to disclose.
© 2015 by the American College of Cardiology Foundation. Published by Elsevier.